• News
  • SAN DIEGO
  • General

La Jolla Pharmaceutical enters agreement with Stanford University

La Jolla Pharmaceutical Co. (Nasdaq: LJPC), a biotechnology company developing therapeutics targeting significant unmet diseases, announced Monday it has signed an option agreement with Stanford University that will add proprietary technology to the company’s programs.

To continue reading, subscribe now
or
log in to your account
User Response
0 UserComments

La Jolla Pharmaceutical Co.

Company Website

6455 Nancy Ridge Dr.
San Diego, CA 92121

Company Trade Data

Stock Symbol Close
Change
Chg %Chg
Volume
52-Week
High Low
LJPC
10.14
  -0.28  
- 2.69%
122,114,000
19.50
3.40

Insider Trade Data

Date Insider Shares Type Value
07/31/2014 Zarrabian, Saiid 381 Purchase $3,631
07/31/2014 Zarrabian, Saiid 381 Purchase $3,631
07/23/2014 Tidmarsh, George F 19,000 Purchase $199,500
05/21/2014 Tidmarsh, George F 12,000 Purchase $88,440
05/21/2014 Tidmarsh, George F 12,000 Purchase $88,440

La Jolla Pharmaceutical Co. Executive(s):

Deirdre Gillespie

  • Chief Executive Officer, President

George Tidmarsh

  • Chief Executive Officer, President

Similar Companies

NAICS - 325412 - Pharmaceutical Preparation Manufacturing
SIC - 2834 - PHARMACEUTICAL PREPARATIONS
SIC - 2835 - IN VITRO AND IN VIVO DIAGNOSTIC SUBSTANCES
NAICS - 541712 - Research and Development in the Physical, Engineering, and Life Sciences (except Biotechnology)
SIC - 3728 - AIRCRAFT PARTS AND AUXILIARY EQUIPMENT, NOT ELSEWHERE CLASSIFIED
SIC - 3769 - GUIDED MISSILE AND SPACE VEHICLE PARTS AND AUXILIARY EQUIPMENT, N
SIC - 3721 - AIRCRAFT
Subscribe Today!